Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5Lymphoid 5Dermatologic 4Other hematologic neoplasm 2Myeloid 1Head & Neck 1Classical hematology 1Breast 1

Conditions

Thyroid Neoplasms 1Aggression 1

Interventions

Cisplatin 136Cetuximab 101pembrolizumab 83Radiotherapy 62Carboplatin 57Radiotherapy, Intensity-Modulated 54Fluorouracil 47Docetaxel 47Nivolumab 44Paclitaxel 37Radiation 21Erlotinib Hydrochloride 19durvalumab 18Platinum 15Ipilimumab 14Gemcitabine 13lenvatinib 12Drug Therapy 12Bevacizumab 12Albumin-Bound Paclitaxel 12vandetanib 11Pemetrexed 11Magnetic Resonance Spectroscopy 111,2-diaminocyclohexaneplatinum II citrate 11Radiosurgery 10Everolimus 10tremelimumab 9epacadostat 9Surgical Procedures, Operative 9Sorafenib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bexarotene × Head & Neck × Clear all
NCT00718770 2014-01-17

A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression

University of Colorado, Denver

Phase EARLY_PHASE1 Completed
10 enrolled 5 charts
Head & Neck

Aggression, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡